세계의 항독소 시장 - 규모, 점유율, 동향 분석 보고서 : 종별, 유형별, 작용기전별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Anti-venom Market Size, Share & Trends Analysis Report By Species (Snake, Scorpion), By Type (Polyvalent, Monovalent), By Mode Of Action (Cytotoxic, Neurotoxic), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,515,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,946,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,809,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

항독소 시장 규모와 동향

세계 항독소 시장 규모는 2023년에 11억 8,000만 달러로 추정되며, 2024-2030년에 걸쳐 CAGR 8.11%를 나타낼 것으로 예측됩니다. 이 성장은 독 물린/자상 유병률 증가, 항독소 치료에 대한 의식 증가, 효과적인 치료법 개발을 위한 연구개발 이니셔티브 증가, 보급을 위한 정부 이니셔티브 증가에 기인하고 있습니다. 세계보건기구(WHO)에 따르면 매년 약 540만 명이 뱀에 씹히고 있습니다. 게다가 뱀에 물린 결과, 세계 전체에서 매년 약 8만 1,410-13만 7,880명이 사망하고 있습니다.

마찬가지로 거미와 전갈 등 여러 독을 가진 종도 항독소 치료 수요 증가에 크게 기여합니다. 이러한 독종에 의한 물린은 호흡을 방해하거나 출혈성 질환을 일으키거나 심지어 돌이킬 수없는 신부전을 일으킬 수있는 심한 마비와 같은 다양한 심각한 상태와 급성 의료 응급 상황 자주 발생합니다. 독에 의한 물린의 이러한 영향과 치료의 필요성에 대한 의식 증가는 예측 기간 동안 시장 성장을 가속할 것으로 예상됩니다. 의료제도와 자원이 취약한 국가나 지역에서는 독 물림으로 인한 이러한 증상의 부담이 증가하기 때문에 이러한 치료의 중요성이 부각되고 있습니다.

다양한 연구기관, 대학, 의료기업들이 보다 나은 결과와 결과를 가져오는 고급 솔루션 개발을 위해 항독소에 대한 연구개발을 강화하기 위해 노력하고 있습니다. 예를 들어, 2022년 10월 말레이시아 모나시 대학과 Agilent Technologies Inc.는 말레이시아에 통합 생물학 센터를 건설하기 위해 MoU에 서명했습니다. 이 센터는 연구 기관의 과학적 지식을 향상시키고 더 나은 항독소 약물 및 기타 응용 생물학 연구를 개발하는 데 도움이 될 것으로 기대됩니다. 마찬가지로 2024년 3월 케냐 영장류 연구소는 아프리카 국가에서 처음으로 생산된 항악성 종양제를 도입할 준비가 되었습니다고 발표했습니다. 다양한 기관의 이러한 연구 이니셔티브는 첨단 치료법의 개발로 이어지고 시장 성장을 가속할 것으로 기대됩니다.

마찬가지로 세계적으로 일부 정부는 독종과 그 물린 영향에 대한 인식을 높이려고 하고 있으며, 이는 시장 성장에 기여할 것으로 예상됩니다. 예를 들어, 2024년 3월, 인도 정부(GOI)의 연방 보건부는 인도에서 뱀 물기의 예방과 통제를 위한 국가 행동 계획(NAP-SE)을 시작했습니다. 또한 뱀 물림 헬프라인도 개설되어 국내 5개 주에서 뱀에게 상해를 입은 개인과 지역사회가 의료를 받을 수 있게 되었습니다. 독물에 의한 물린 피해자들에 대한 의료 접근을 향상시키기 위한 이러한 정부 이니셔티브 증가는 예측 기간 동안 항독소 시장의 성장을 가속할 것으로 예상됩니다.

시장 세분화

이 보고서는 세계, 지역 및 국가 수준에서 수익 성장을 예측하고 2018-2030년 각 하위 부문에 대한 최신 업계 동향 분석을 제공합니다. 이 연구에서 Grand View Research, Inc.는 종, 유형, 작용기전, 최종 용도 및 지역을 기반으로 세계의 베놈 대책 시장 보고서를 세분화합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 항독소 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 상위 시장 전망
  • 관련/보조적인 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 항독소 시장 분석 도구
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 항독소 시장 : 종, 추정·동향 분석

• 종 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 종별 세계의 항독소 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석

제5장 항독소 시장 : 유형, 추정·동향 분석

• 유형 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 유형별 세계의 항독소 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석

제6장 항독소 시장 : 작용기전, 추정·동향 분석

• 작용기전 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 작용기전별 세계의 항독소 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석

제7장 항독소 시장 : 최종 용도, 추정·동향 분석

• 최종 용도 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 최종 용도별 세계의 항독소 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석

제8장 항독소 시장 : 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2023년과 2030년
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 기업의 시장 점유율 분석, 2023년
  • Bharat Serums and Vaccines Limited(BSV)
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • CSL Limited
  • Haffkine Bio-Pharmaceutical Corporation Limited
  • Incepta Pharmaceuticals Limited
  • Merck &Co., Inc.
  • Pfizer, Inc.
  • MicroPharm Limited
  • Rare Disease Therapeutics Inc.
  • South African Vaccine Producers(Pty) Ltd.
  • Medtoxin Venom Laboratories
  • Instittue of Immunology
  • Alomone Labs, Ltd.
  • Sigma Aldrich

JHS

영문 목차

영문목차

Anti-venom Market Size & Trends

The global anti-venom market size was estimated at USD 1.18 billion in 2023 and is expected to grow at a CAGR of 8.11% from 2024 to 2030. This growth is attributed to the rising prevalence of venom bites/stings, increasing awareness of anti-venom treatments, growing research initiatives to develop effective treatments, and growing government initiatives to spread. According to the World Health Organization (WHO), approximately 5.4 million people get bitten by snakes each year. Moreover, around 81 410 to 137 880 mortalities occur globally each year as a result of snake bites.

Similarly, several venomous species, such as spiders, scorpions, and others, also significantly contribute to the increasing demand for anti-venom treatments. Bites from these venomous species often lead to various serious conditions and acute medical emergencies such as severe paralysis, which may prevent breathing, lead to bleeding disorders, and may even cause irreversible kidney failure. The increasing awareness about these effects of venom bites and the need for their treatment are expected to fuel the market growth over the forecast period. The countries and regions with weaker health systems and resources experience an increased burden of these conditions caused by venom bites, highlighting the importance of these treatments.

Various research institutes, universities, and healthcare companies are taking initiatives to enhance their R&D on anti-venom for the development of advanced solutions with better results and outcomes. For instance, in October 2022, Monash University Malaysia and Agilent Technologies Inc. signed a MoU for building an integrated biology center in Malaysia. This center is anticipated to help the institutions improve their scientific knowledge to develop better anti-venom & other applied biology research. Similarly, in March 2024, the Institute for Primate Research Kenya announced that it is ready to introduce the first-ever anti-venom produced in any African country. Such research initiatives taken by various institutions are expected to lead to the development of advanced treatments and drive market growth.

Similarly, several governments globally are trying to increase awareness about venomous species and the effects of their bites, which is further anticipated to contribute to market growth. For instance, in MAR 2024, the Union Health Ministry of the Government of India (GOI) launched the National Action Plan for Prevention and Control of Snakebite Envenoming (NAP-SE) in India. A snakebite helpline no was also launched at the event to ensure better access to medical care for the individuals or communities affected by snakebites in five different states of the country. Such increasing government initiatives to increase medical care access for venom bite victims are anticipated to fuel the anti-venom market growth over the forecast period.

Global Anti-venom Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global anti-venom market report based on species, type, mode of action, end-use, and region:

• Species Outlook (Revenue, USD Million, 2018 - 2030)
• Snake
• Common Cobra
• Common Krait
• Russell Viper
• Others
• Scorpion
• Spider
• Other Species
• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Polyvalent
• Monovalent
• Mode Of Action Outlook (Revenue, USD Million, 2018 - 2030)
• Cytotoxic
• Neurotoxic
• Haemotoxic
• Cardiotoxic
• Myotoxic
• Others
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Regional Outlook (Revenue in USD Million, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

• Latin America

Brazil

Argentina

• Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Species
  • 1.2.2. Type
  • 1.2.3. Mode of Action
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Species outlook
  • 2.2.2. Type outlook
  • 2.2.3. Mode of Action outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Anti-Venom Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidents of venom-bites
    • 3.2.1.2. Increasing R&D initiatives
    • 3.2.1.3. Increasing awareness about importance of anti-venom
    • 3.2.1.4. Rising government initiatives
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited access to the treatments
• 3.3. Anti-Venom Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
  • 3.3.2. PESTEL Analysis

Chapter 4. Anti-Venom Market: Species Estimates & Trend Analysis

• 4.1. Species Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Anti-Venom Market by Species Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Snakes
    • 4.4.1.1. Snakes market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Common cobra
    • 4.4.1.2.1. Common cobra market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Common krait
    • 4.4.1.3.1. Common krait market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Rusell viper
    • 4.4.1.4.1. Rusell viper market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.5. Others
    • 4.4.1.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Scorpion
    • 4.4.2.1. Scorpion market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Spider
    • 4.4.3.1. Spider market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Other species
    • 4.4.4.1. Other species market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Anti-Venom Market: Type Estimates & Trend Analysis

• 5.1. Type Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Anti-Venom Market by Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Polyvalent
    • 5.4.1.1. Polyvalent market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Monovalent
    • 5.4.2.1. Monovalent market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Anti-Venom Market: Mode of Action Estimates & Trend Analysis

• 6.1. Mode of action Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Anti-Venom Market by Mode of Action Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Cytotoxic
    • 6.4.1.1. Cytotoxic market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Neurotoxic
    • 6.4.2.1. Neurotoxic market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Haemotoxic
    • 6.4.3.1. Haemotoxic market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Cardiotoxic
    • 6.4.4.1. Cardiotoxic market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Myotoxic
    • 6.4.5.1. Myotoxic market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Anti-Venom Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Anti-Venom Market by End Use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Hospitals
    • 7.4.1.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Clinics
    • 7.4.2.1. Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Ambulatory surgical centers
    • 7.4.3.1. Ambulatory surgical centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Others
    • 7.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Anti-Venom Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. North America
  • 8.5.2. U.S.
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. Europe
  • 8.6.2. UK
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ Reimbursement
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ Reimbursement
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. France
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ Reimbursement
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ Reimbursement
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Denmark
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ Reimbursement
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.9. Norway
    • 8.6.9.1. Key country dynamics
    • 8.6.9.2. Regulatory framework
    • 8.6.9.3. Competitive scenario
    • 8.6.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Asia Pacific
  • 8.7.2. Japan
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ Reimbursement
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. China
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ Reimbursement
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. India
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ Reimbursement
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. Australia
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ Reimbursement
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. South Korea
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ Reimbursement
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.7. Thailand
    • 8.7.7.1. Key country dynamics
    • 8.7.7.2. Regulatory framework/ Reimbursement
    • 8.7.7.3. Competitive scenario
    • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Latin America
  • 8.8.2. Brazil
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/ Reimbursement
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. MEA
  • 8.9.2. South Africa
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ Reimbursement
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. Saudi Arabia
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ Reimbursement
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. UAE
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ Reimbursement
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.5. Kuwait
    • 8.9.5.1. Key country dynamics
    • 8.9.5.2. Regulatory framework
    • 8.9.5.3. Competitive scenario
    • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. Bharat Serums and Vaccines Limited (BSV)
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Others benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Boehringer Ingelheim International GmbH
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Others benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Boston Scientific Corporation
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Others benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. CSL Limited
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Others benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Haffkine Bio-Pharmaceutical Corporation Limited
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Others benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Incepta Pharmaceuticals Limited
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Others benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Merck & Co., Inc.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Others benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Pfizer, Inc.
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Others benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. MicroPharm Limited
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Others benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Rare Disease Therapeutics Inc.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Others benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. South African Vaccine Producers (Pty) Ltd.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Others benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. Medtoxin Venom Laboratories
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Others benchmarking
    • 9.3.15.4. Strategic initiatives
  • 9.3.16. Instittue of Immunology
    • 9.3.16.1. Company overview
    • 9.3.16.2. Financial performance
    • 9.3.16.3. Others benchmarking
    • 9.3.16.4. Strategic initiatives
  • 9.3.17. Alomone Labs, Ltd.
    • 9.3.17.1. Company overview
    • 9.3.17.2. Financial performance
    • 9.3.17.3. Others benchmarking
    • 9.3.17.4. Strategic initiatives
  • 9.3.18. Sigma Aldrich
    • 9.3.18.1. Company overview
    • 9.3.18.2. Financial performance
    • 9.3.18.3. Others benchmarking
    • 9.3.18.4. Strategic initiatives

관련자료